Back From the Dead: What Dog Cloning Means for Our Human Future
By Osagie K. Obasogie,
Alternet
| 06. 16. 2008
Good Morning America recently televised a world exclusive that caught many pet owners' attention: Dog cloning is now commercially available for people who want to bring their dead and dying companions back to life. Brought to you by BioArts International, a Northern California biotech startup, man and his dead best friend can now be, as the company's marketing slogan states, "Best Friends Again." And again. And again.
But it'll cost you. Rather than taking orders, BioArts will auction off five dog cloning slots in mid-June. Bids start at $100,000.
Despite Good Morning America's numerous awards for excellence in televised journalism, its coverage of this story was not its finest moment. A number of omissions and oversights led the segment to present dog cloning as a largely unproblematic way to deal with the grief of our pets' inevitable deaths. But several untold stories behind this story need to be put front and center.
The ABC morning show presented BioArts' CEO Lou Hawthorne as the next in a long line of pioneering Californian bio executives. But rather than being a new venture...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...